CPH.TO vs. ADMA
CPH.TO (Cipher Pharmaceuticals Inc.) and ADMA (ADMA Biologics, Inc.) are both stocks. Both are in the Healthcare sector — CPH.TO in Drug Manufacturers - Specialty & Generic, ADMA in Biotechnology. Over the past 10 years, CPH.TO returned 8.60%/yr vs 1.44%/yr for ADMA. At a 0.05 correlation, their price movements are largely independent.
Performance
CPH.TO vs. ADMA - Performance Comparison
Loading charts...
Different Trading Currencies
CPH.TO is traded in CAD, while ADMA is traded in USD. To make them comparable, the ADMA values have been converted to CAD using the latest available exchange rates.
Returns By Period
In the year-to-date period, CPH.TO achieves a 11.22% return, which is significantly higher than ADMA's -55.62% return. Over the past 10 years, CPH.TO has outperformed ADMA with an annualized return of 8.60%, while ADMA has yielded a comparatively lower 1.44% annualized return.
CPH.TO
- 1D
- 1.39%
- 1M
- -6.42%
- YTD
- 11.22%
- 6M
- 14.73%
- 1Y
- 36.62%
- 3Y*
- 61.86%
- 5Y*
- 63.58%
- 10Y*
- 8.60%
ADMA
- 1D
- 0.08%
- 1M
- -19.17%
- YTD
- -55.62%
- 6M
- -59.49%
- 1Y
- -59.26%
- 3Y*
- 26.85%
- 5Y*
- 39.53%
- 10Y*
- 1.44%
CPH.TO vs. ADMA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CPH.TO Cipher Pharmaceuticals Inc. | 11.22% | 5.17% | 158.48% | 44.27% | 116.95% | 90.32% | -38.00% | -12.28% | -65.10% | 0.00% |
ADMA ADMA Biologics, Inc. | -55.62% | 1.48% | 312.02% | 13.93% | 194.79% | -28.35% | -52.07% | 59.14% | -19.23% | -41.30% |
Correlation
The correlation between CPH.TO and ADMA is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.06 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.14 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.10 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.06 |
Correlation (All Time) Calculated using the full available price history since Oct 18, 2013 | 0.05 |
Fundamentals
CPH.TO:
CA$432.22M
ADMA:
$1.91B
CPH.TO:
CA$1.19
ADMA:
$0.68
CPH.TO:
14.11
ADMA:
11.77
CPH.TO:
8.58
ADMA:
3.82
CPH.TO:
3.25
ADMA:
4.90
CPH.TO:
CA$50.92M
ADMA:
$509.86M
CPH.TO:
CA$37.95M
ADMA:
$312.42M
CPH.TO:
CA$25.12M
ADMA:
$218.74M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CPH.TO vs. ADMA — Risk / Return Rank
CPH.TO
ADMA
CPH.TO vs. ADMA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Cipher Pharmaceuticals Inc. (CPH.TO) and ADMA Biologics, Inc. (ADMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CPH.TO | ADMA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.91 | ||
| Sortino ratioReturn per unit of downside risk | +3.34 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 0.78 | +0.41 |
| Calmar ratioReturn relative to maximum drawdown | 1.52 | -0.92 | +2.44 |
| Martin ratioReturn relative to average drawdown | 3.23 | -1.80 | +5.03 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CPH.TO | ADMA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.82 | -1.10 | +1.91 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 1.28 | 0.67 | +0.61 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.14 | 0.02 | +0.12 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.08 | 0.03 | +0.06 |
Drawdowns
CPH.TO vs. ADMA - Drawdown Comparison
The maximum CPH.TO drawdown since its inception was -97.90%, which is greater than ADMA's maximum drawdown of -90.48%. Use the drawdown chart below to compare losses from any high point for CPH.TO and ADMA.
Loading charts...
Drawdown Indicators
| CPH.TO | ADMA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.90% | -90.48% | -7.42% |
Max Drawdown (1Y)Largest decline over 1 year | -22.83% | -64.81% | +41.98% |
Max Drawdown (3Y)Largest decline over 3 years | -42.50% | -68.97% | +26.47% |
Max Drawdown (5Y)Largest decline over 5 years | -42.50% | -68.97% | +26.47% |
Max Drawdown (10Y)Largest decline over 10 years | -94.64% | -86.72% | -7.92% |
Current DrawdownCurrent decline from peak | -15.15% | -67.23% | +52.08% |
Average DrawdownAverage peak-to-trough decline | -61.46% | -48.99% | -12.47% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.77% | 32.88% | -22.11% |
Volatility
CPH.TO vs. ADMA - Volatility Comparison
The current volatility for Cipher Pharmaceuticals Inc. (CPH.TO) is 13.90%, while ADMA Biologics, Inc. (ADMA) has a volatility of 20.68%. This indicates that CPH.TO experiences smaller price fluctuations and is considered to be less risky than ADMA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CPH.TO | ADMA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.90% | 20.68% | -6.78% |
Volatility (6M)Calculated over the trailing 6-month period | 28.46% | 45.02% | -16.56% |
Volatility (1Y)Calculated over the trailing 1-year period | 42.66% | 54.27% | -11.61% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 49.98% | 59.17% | -9.19% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 60.76% | 68.88% | -8.12% |
Dividends
CPH.TO vs. ADMA - Dividend Comparison
Neither CPH.TO nor ADMA has paid dividends to shareholders.
Financials
CPH.TO vs. ADMA - Financials Comparison
This section allows you to compare key financial metrics between Cipher Pharmaceuticals Inc. and ADMA Biologics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CPH.TO vs. ADMA - Profitability Comparison
CPH.TO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cipher Pharmaceuticals Inc. reported a gross profit of 8.35M and revenue of 12.30M. Therefore, the gross margin over that period was 67.9%.
ADMA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported a gross profit of 80.75M and revenue of 114.49M. Therefore, the gross margin over that period was 70.5%.
CPH.TO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cipher Pharmaceuticals Inc. reported an operating income of 5.50M and revenue of 12.30M, resulting in an operating margin of 44.7%.
ADMA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported an operating income of 58.27M and revenue of 114.49M, resulting in an operating margin of 50.9%.
CPH.TO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cipher Pharmaceuticals Inc. reported a net income of 6.06M and revenue of 12.30M, resulting in a net margin of 49.3%.
ADMA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported a net income of 45.33M and revenue of 114.49M, resulting in a net margin of 39.6%.
Frequently Asked Questions
CPH.TO and ADMA have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for CPH.TO and ADMA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer